DISCLAIMER: THIS PAGE IS INTENDED FOR HEALTHCARE PROFESSIONALS AND OTHER RELEVANT DECISION MAKERS IN Slovenia ONLY.
Information about the NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted) (also known as NVX-CoV2373)
NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted) has been granted a conditional marketing authorisation for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
Report an Adverse Event (AE)
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system of Slovenia.
Javna agencija Republike Slovenije za zdravila in medicinske pripomočke
Sektor za farmakovigilanco
Nacionalni center za farmakovigilanco
Slovenčeva ulica 22
Tel: +386 8 2000 500
Faks: +386 8 2000 510
e-pošta: [email protected]
spletna stran: www.jazmp.si
Tel: +386 1 888 83 23
09:00 - 17:00
Monday - Friday